Istradefylline Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg, 40 mg

Reference Brands: Nourianz(USA)

Category: Neurology

Istradefylline is available in Tablets and strengths such as 20 mg, 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Istradefylline is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Istradefylline can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Istradefylline, marketed under the brand name Nourianz, is an oral medication used as an adjunctive treatment for adults with Parkinson’s disease who experience “off” episodes while on levodopa/carbidopa therapy. These “off” episodes are periods when the primary Parkinson’s medications are not providing adequate symptom control, leading to worsening motor symptoms such as tremor, stiffness, and difficulty walking. Istradefylline functions as a selective adenosine A2A receptor antagonist, targeting pathways that help regulate motor control and reduce the frequency and duration of these off periods. By adding istradefylline to existing levodopa/carbidopa therapy, patients may experience more consistent symptom relief and improved daily functioning. The medication is administered orally in 20 mg or 40 mg tablets, under the guidance of a healthcare professional, with dosing individualized based on patient response and tolerance. Istradefylline is generally well tolerated, with reported adverse effects including mild dyskinesia, dizziness, constipation, and insomnia, while serious liver toxicity is rare. Its mechanism and targeted action make it a valuable treatment option for Parkinson’s patients seeking improved motor symptom management during long-term levodopa therapy.